How to Treat Severe Lung Infections Using Ceftolozane and Tazobactam

A medical treatment method for severe, hospital-acquired pneumonia using a specific, recurring intravenous dose of the antibiotic combination ceftolozane and tazobactam.

What it covers

The patent outlines a specific medical regimen for treating pneumonia, particularly infections acquired in hospital settings or via ventilators. It requires the intravenous administration of 2.0 grams of the antibiotic ceftolozane, combined with tazobactam, every 8 hours. The claims specify that this infusion should last for 60 minutes to be effective against common, stubborn pathogens like Pseudomonas aeruginosa, E. coli, and K. pneumoniae.

What it doesn't cover

• —Does not cover oral administration of these antibiotics.
• —Does not cover dosages other than the specified 2.0 grams of ceftolozane.
• —Does not cover treatment regimens administered at intervals other than every 8 hours.
• —Does not cover the chemical synthesis of the drugs themselves.

The clever bit

The innovation lies in identifying the precise 'pharmacokinetic window'—the specific dose and 8-hour frequency—that maintains enough of the drug in the lungs to effectively kill resistant bacteria without causing toxicity.

Why it matters

This patent protects a specific clinical dosing protocol for a potent antibiotic combination. By defining the exact dosage and timing required to fight resistant hospital-acquired pneumonia, it provides a clear legal framework for how this medication is prescribed and marketed in clinical settings.

Real-world examples

• 1.Zerbaxa (a commercial antibiotic product containing ceftolozane and tazobactam)